<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01072864</url>
  </required_header>
  <id_info>
    <org_study_id>200917508-1</org_study_id>
    <nct_id>NCT01072864</nct_id>
  </id_info>
  <brief_title>Effects of California Walnuts on Vascular Function in Postmenopausal Women</brief_title>
  <official_title>Effects of California Walnuts on Vascular Function in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California Walnut Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the potential acute cardiovascular benefits of California Walnuts in&#xD;
      postmenopausal women of ages 55-70.&#xD;
&#xD;
      Primary outcome measures:&#xD;
&#xD;
        -  Vascular function&#xD;
&#xD;
        -  Platelet reactivity&#xD;
&#xD;
      We hypothesize that the consumption of California walnuts will improve vascular function and&#xD;
      platelet reactivity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epidemiological studies have shown that consumption of high amounts of plant foods, such as&#xD;
      nuts, fruits and vegetables, appears to be protective against chronic diseases including&#xD;
      heart disease, stroke, diabetes mellitus and metabolic syndrome. In recent years, numerous&#xD;
      studies indicate that consumption of walnuts mainly containing α-linolenic acid (ALA),&#xD;
      L-arginine and polyphenols beneficially alters vascular function and reduces inflammatory&#xD;
      biomarkers. Recent studies have reported that consumption of walnuts is associated with&#xD;
      beneficial effects in prevention of chronic diseases by favorably altering human serum&#xD;
      profiles (i.e. decrease in LDL cholesterol and triglycerides and increase in HDL cholesterol&#xD;
      and apolipoprotein A1) which are closely involved in the development of cardiovascular&#xD;
      disease (CVD). In addition, recent reports by Dr. Ros and his colleagues indicate that&#xD;
      addition of walnuts to a high-fat meal can improve endothelial function. This favorable&#xD;
      influence on vasoactivity has been attributed to the antioxidant and anti-inflammatory&#xD;
      properties of components of walnuts.&#xD;
&#xD;
      Due to their age and menopausal status, postmenopausal women in particular, are at a greater&#xD;
      risk population for developing CVD. Males tend to show greater rates of CVD than&#xD;
      pre-menopausal women, while women following menopause show an increase in the rates of CVD.&#xD;
      This increase is associated with endothelial dysfunction and decreased vasodilation which are&#xD;
      apparently expressed after menopause and become worse with age. In this study, we will define&#xD;
      the effects of consuming California walnuts on vascular health.&#xD;
&#xD;
      We hypothesize that consumption of California walnuts, which are particularly rich in ALA,&#xD;
      L-arginine and polyphenols, will improve endothelial function and platelet reactivity in an&#xD;
      at-risk population of postmenopausal women 50-70 years of age.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral Arterial Tonometry (PAT)</measure>
    <time_frame>2 and 4 hours</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>5 g of walnuts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>20 g of walnuts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>30 g of walnuts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>40 g of walnuts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Walnuts</intervention_name>
    <description>Consumption of 5 g of walnuts.</description>
    <arm_group_label>5 g of walnuts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Walnuts</intervention_name>
    <description>Consumption of 20 g of walnuts.</description>
    <arm_group_label>20 g of walnuts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Walnuts</intervention_name>
    <description>Consumption of 30 g of walnuts.</description>
    <arm_group_label>30 g of walnuts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Walnuts</intervention_name>
    <description>Consumption of 40 g of walnuts.</description>
    <arm_group_label>40 g of walnuts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  50 to 70 years of age&#xD;
&#xD;
          -  Lack of menses in the last year and FSH 23-116.3 mlU/mL&#xD;
&#xD;
          -  Subject is willing and able to comply with the study protocols.&#xD;
&#xD;
          -  Subject is willing to consume up to 40 g of California walnuts.&#xD;
&#xD;
          -  BMI 18.5-34.9 kg/m2&#xD;
&#xD;
          -  Weight ≥ 110 pounds&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI ≥ 35 kg/m2&#xD;
&#xD;
          -  Weight &lt;110 pounds&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Taking anticoagulation medication including NSAIDs&#xD;
&#xD;
          -  Blood pressure ≥ 160/90 mm Hg&#xD;
&#xD;
          -  PFA-100 readings 10 % outside of normal reference range (normal reference range for&#xD;
             ADP-Collagen: 71-118 sec; Epinephrine-Collagen: 94-193 sec).&#xD;
&#xD;
          -  Renal or liver disease&#xD;
&#xD;
          -  Heart disease, which includes cardiovascular events and Stroke&#xD;
&#xD;
          -  Cushing's syndrome&#xD;
&#xD;
          -  Chronic/routine high intensity exercise&#xD;
&#xD;
          -  Inability to properly place or wear the PAT probes or abnormal measurements on&#xD;
             pre-screening PAT&#xD;
&#xD;
          -  Abnormal Liver, CBC or CMP (laboratory values outside the reference range) if&#xD;
             determined to be clinically significant.&#xD;
&#xD;
          -  History of cancer&#xD;
&#xD;
          -  History of psychiatric disorders i.e. schizophrenia or bi-polar or depression treated&#xD;
             with antidepressants within the last 1 year.&#xD;
&#xD;
          -  Use of MAOI inhibitor within the last 1 year (e.g. phenelzine (Nardil),&#xD;
             tranylcypromine (Parnate), etc)&#xD;
&#xD;
          -  Malabsorption&#xD;
&#xD;
          -  Anxiety medications&#xD;
&#xD;
          -  Routine use of prescription drugs or over-the counter medications, which may&#xD;
             potentially modulate the outcome of this study; including antibiotics, aspirin and&#xD;
             aspirin-containing formulations, COX-2 inhibitors, antihistamines, corticosteroids,&#xD;
             ACE-inhibitors, and beta-blockers.&#xD;
&#xD;
          -  Asthma (can be worsened by mild to moderate food allergies).&#xD;
&#xD;
          -  Indications of substance or alcohol abuse within the last 3 years&#xD;
&#xD;
          -  Use of multivitamin/mineral supplements&#xD;
&#xD;
          -  Use of herbal or plant-based supplements; omega-3 fatty acids, and fish oils in the&#xD;
             past 3-6 months.&#xD;
&#xD;
          -  Nut allergies&#xD;
&#xD;
          -  Soy-derived supplements&#xD;
&#xD;
          -  Soy/soy products consumption &gt; 2 servings/week&#xD;
&#xD;
          -  Hormone replacement therapy&#xD;
&#xD;
          -  Alcohol consumption &gt; 1 drink/day (i.e. 1 bottle of beer, ½ glass of wine, and 1 shot&#xD;
             of hard liquor)&#xD;
&#xD;
          -  Fruit consumption ≥ 3 cups (6 servings)/day&#xD;
&#xD;
          -  Vegetable consumption ≥ 4 cups (8 servings)/day&#xD;
&#xD;
          -  Grain consumption ≥ 8 oz/day&#xD;
&#xD;
          -  Meat and Beans ≥ 7 oz/day&#xD;
&#xD;
          -  Fatty Fish ≥ 3 times/week&#xD;
&#xD;
          -  Milk ≥ 5 cups/day&#xD;
&#xD;
          -  Oil ≥ 8 tsp/day&#xD;
&#xD;
          -  Coffee/tea ≥ 3 cups/day&#xD;
&#xD;
          -  Dark chocolate ≥ 3 oz/day&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert M. Hackman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ragle Human Nutrition Research Center</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>February 18, 2010</study_first_submitted>
  <study_first_submitted_qc>February 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2010</study_first_posted>
  <last_update_submitted>October 28, 2010</last_update_submitted>
  <last_update_submitted_qc>October 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Robert M. Hackman</name_title>
    <organization>University of California, Davis</organization>
  </responsible_party>
  <keyword>Postmenopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

